Answers are grounded in this paper and cite their sources.
Introduction This study investigated the efficacy and safety of teneligliptin as an add‐on therapy in Korean patients with type 2 diabetes inadequately controlled with empagliflozin and metformin. Materials and Methods In this multicenter, double‐blind, randomized, placebo‐controlled phase 3 trial, participants with glycated hemoglobin (HbA1c) levels 7.0–10.5% treated with empagliflozin 10 mg plus metformin (≥1,000 mg/day) were randomly assigned to receive teneligliptin 20 mg once daily ( n = 116) or placebo ( n = 119). The primary endpoint was the change in HbA1c from baseline at week 24, and secondary endpoints included changes in fasting plasma glucose (FPG), achievement rate of target HbA1c, and metabolic parameters. Results At week 24, the teneligliptin group showed a significant reduction in HbA1c compared with the placebo group (least‐squares mean difference −0.69%; 95% confidence interval −0.83 to −0.54; P < 0.0001). The proportion of participants achieving HbA1c < 7.0% was significantly higher in the teneligliptin group (59.5% vs 21.9%; P < 0.0001). Teneligliptin also resulted in significant reductions in FPG and glycated albumin compared with placebo. The treatment was well tolerated, with no significant difference in the incidence of treatment‐emergent adverse events between the groups. Discussion The addition of teneligliptin to empagliflozin and metformin therapy resulted in a significant improvement in glycemic control with a favorable safety profile in Korean patients with type 2 diabetes inadequately controlled with the dual therapy. Teneligliptin can be a viable option for patients who do not achieve adequate glycemic control with empagliflozin and metformin.
No takes yet. Share an insight, caveat, or question.
Kwak et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: